AU2016258188B2 - Histone deacetylase inhibitors and compositions and methods of use thereof - Google Patents

Histone deacetylase inhibitors and compositions and methods of use thereof Download PDF

Info

Publication number
AU2016258188B2
AU2016258188B2 AU2016258188A AU2016258188A AU2016258188B2 AU 2016258188 B2 AU2016258188 B2 AU 2016258188B2 AU 2016258188 A AU2016258188 A AU 2016258188A AU 2016258188 A AU2016258188 A AU 2016258188A AU 2016258188 B2 AU2016258188 B2 AU 2016258188B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
mixture
azabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016258188A
Other languages
English (en)
Other versions
AU2016258188A1 (en
Inventor
Perla Breccia
Celia Dominguez
Alan F. HAUGHAN
Rebecca E. Jarvis
Christopher A. LUCKHURST
Michel C. Maillard
Elizabeth A. Saville-Stones
Andrew J. STOTT
Amanda VAN DE POËL
Michael Wall
Grant Wishart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHDI Foundation
Original Assignee
CHDI Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHDI Foundation filed Critical CHDI Foundation
Publication of AU2016258188A1 publication Critical patent/AU2016258188A1/en
Application granted granted Critical
Publication of AU2016258188B2 publication Critical patent/AU2016258188B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AU2016258188A 2015-05-07 2016-05-06 Histone deacetylase inhibitors and compositions and methods of use thereof Active AU2016258188B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158363P 2015-05-07 2015-05-07
US62/158,363 2015-05-07
PCT/US2016/031335 WO2016179554A1 (en) 2015-05-07 2016-05-06 Histone deacetylase inhibitors and compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2016258188A1 AU2016258188A1 (en) 2017-11-23
AU2016258188B2 true AU2016258188B2 (en) 2021-08-26

Family

ID=57218014

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016258188A Active AU2016258188B2 (en) 2015-05-07 2016-05-06 Histone deacetylase inhibitors and compositions and methods of use thereof

Country Status (11)

Country Link
US (2) US10053434B2 (enExample)
EP (1) EP3291810B1 (enExample)
JP (1) JP6805172B2 (enExample)
KR (1) KR20180002729A (enExample)
CN (1) CN107735088B (enExample)
AU (1) AU2016258188B2 (enExample)
CA (1) CA2984618C (enExample)
EA (1) EA036965B1 (enExample)
IL (1) IL255448B2 (enExample)
MX (1) MX378983B (enExample)
WO (1) WO2016179554A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2984618C (en) * 2015-05-07 2024-01-09 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
EA035592B1 (ru) 2015-05-07 2020-07-13 Сиэйчдиай Фаундэйшн, Инк. Ингибиторы деацетилаз гистонов и композиции и способы их применения
WO2018015447A1 (en) * 2016-07-22 2018-01-25 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
CN109627207A (zh) * 2018-12-17 2019-04-16 天津药明康德新药开发有限公司 一种3-(二氟甲氧基)哌啶盐酸盐的制备方法
CN114727974A (zh) 2019-07-30 2022-07-08 艾科尼佐治疗股份有限公司 Hdac6抑制剂及其用途
WO2022169985A1 (en) 2021-02-03 2022-08-11 Eikonizo Therapeutics, Inc. Hdac6 inhibitors and uses thereof
WO2022174193A1 (en) * 2021-02-15 2022-08-18 The Research Foundation For The State University Of New York Radiolabeled compositions and methods of use thereof
AU2023250964A1 (en) 2022-04-08 2024-11-07 Eikonizo Therapeutics, Inc. Oxadiazole hdac6 inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006408A1 (en) * 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013008162A1 (en) * 2011-07-08 2013-01-17 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006061638A2 (en) 2004-12-10 2006-06-15 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Heterocycle derivatives as histone deacetylase (hdac) inhibitors
KR101781663B1 (ko) 2010-01-13 2017-09-25 템페로 파마슈티칼즈, 인크. 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009830A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
SG2014012926A (en) * 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013066835A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066833A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
CA2856334A1 (en) * 2011-11-28 2013-06-06 Christina Hebach Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
JP6275690B2 (ja) * 2012-04-05 2018-02-07 シーエイチディーアイ ファウンデーション,インコーポレーテッド キヌレニン−3−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
EA035592B1 (ru) 2015-05-07 2020-07-13 Сиэйчдиай Фаундэйшн, Инк. Ингибиторы деацетилаз гистонов и композиции и способы их применения
CA2984618C (en) * 2015-05-07 2024-01-09 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
HRP20230052T1 (hr) 2015-07-27 2023-03-03 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
BR112017027798B1 (pt) 2015-07-27 2023-12-19 Chong Kun Dang Pharmaceutical Corp Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
HRP20220003T1 (hr) 2015-08-04 2022-04-01 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006408A1 (en) * 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
WO2013008162A1 (en) * 2011-07-08 2013-01-17 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease

Also Published As

Publication number Publication date
IL255448B2 (en) 2023-07-01
HK1252487A1 (en) 2019-05-24
US20190202795A1 (en) 2019-07-04
IL255448B1 (en) 2023-03-01
BR112017023711A2 (pt) 2018-07-17
WO2016179554A1 (en) 2016-11-10
MX378983B (es) 2025-03-10
CN107735088B (zh) 2021-11-02
EP3291810B1 (en) 2022-08-10
US20160326124A1 (en) 2016-11-10
CA2984618A1 (en) 2016-11-10
IL255448A0 (en) 2017-12-31
JP2018515489A (ja) 2018-06-14
EP3291810A1 (en) 2018-03-14
CN107735088A (zh) 2018-02-23
AU2016258188A1 (en) 2017-11-23
CA2984618C (en) 2024-01-09
MX2017014300A (es) 2018-08-09
EP3291810A4 (en) 2018-11-07
EA036965B1 (ru) 2021-01-20
US10053434B2 (en) 2018-08-21
JP6805172B2 (ja) 2020-12-23
KR20180002729A (ko) 2018-01-08
EA201792247A1 (ru) 2018-06-29

Similar Documents

Publication Publication Date Title
AU2016256917B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US10053434B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US9783488B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US10106535B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EP2667709A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
WO2014159214A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
CA3156783A1 (en) Tricycle dihydroimidazopyrimidone derivative, preparation method thereof, pharmaceutical composition and use thereof
HK1252487B (en) Histone deacetylase inhibitors and compositions and methods of use thereof
HK1252489B (en) Histone deacetylase inhibitors and compositions and methods of use thereof
BR112017023711B1 (pt) Inibidores de histona deacetilase e composições e métodos de uso dos mesmos

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)